Collecting blood samples from patients undergoing plasma exchange
Official title: Assessment of Changes in Normal and Pathological Immune Factors in Patients Undergoing Plasma Exchange
Run by University of Iowa · NCT05004493 · Data updated 2026-11-12
This study is collecting blood samples from patients with immune-related diseases who are having plasma exchange to see how their antibody levels change during treatment and to use the samples for future research.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years to 99 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University of Iowa Academic / other |
| Locations | 1 site (Iowa City, Iowa) |
| Status | Recruiting |
| Started | July 28, 2021 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2040 |
| Registry record updated | May 20, 2025 |
| Trial ID | NCT05004493 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients undergoing plasma exchange therapy for conditions like antibody-mediated rejection, NMO spectrum disorder, TTP, or CIDP.
✕Probably not a fit
Patients not undergoing plasma exchange therapy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients with immune-mediated diseases who undergo plasma exchange procedures to remove harmful antibodies. The study aims to collect and cryopreserve blood biospecimens, including plasma, serum, and PBMCs, for current and future research. Patients will be consented for participation shortly after being referred for plasma exchange, and the study will monitor antibody levels and BAFF levels in their blood throughout the treatment process. Importantly, participation will not alter the standard treatment plan for these patients.
Why it matters
Potential benefit: If successful, this study could enhance understanding of antibody-mediated diseases and improve future treatment strategies.
How similar studies have gone: While this study is observational and focuses on biospecimen collection, similar studies have shown success in understanding immune-mediated diseases through plasma exchange.
Who can join: the full rules
Show full inclusion / exclusion criteria
Pts undergoing plasma exchange therapy are eligible to be in this protocol
Where it's running
-
DeGowin blood Center
Iowa City, Iowa, United States Recruiting
Study contacts
- Study coordinator: Charles Knudson, MD, PHD
- Email: c-knudson@uiowa.edu
- Phone: +1 319 467-5129
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CID-103 for active and chronic active ABMR in kidney transplant patients
A two-part study will test CID-103, an anti-CD38 infusion, to see if it is safe and helps adults with active or chronic active antibody-mediated rejection after kidney transplant.
-
Noninvasive transcranial temporal interference stimulation for neuropathic pain in NMOSD
Researchers will try noninvasive transcranial temporal interference stimulation to reduce chronic neuropathic pain in adults with neuromyelitis optica spectrum disorder (NMOSD).
-
Real-world efgartigimod use in adults with CIDP
This study will see if efgartigimod helps adults with CIDP when given as part of routine clinical care.
-
Empasiprubart for adults with CIDP
This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.
-
BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases
This trial will try personalized BAFF‑R CAR T cells to reduce disease activity in people with hard‑to‑treat conditions such as CIDP, NMOSD, myasthenia gravis, and inflammatory myopathies.
-
Empasiprubart versus IVIg for treating CIDP in adults
This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.